Testing and Treatment for Lyme Disease
Lyme disease is a multisystem inflammatory disease caused by the spirochete Borrelia (B.) burgdorferi and transmitted by the bite of an infected tick. The disease is characterized by stages, beginning with localized infection of the skin, followed by dissemination to many sites. Diagnostic testing for Lyme disease is challenging and can lead to overdiagnosis and overtreatment. While most manifestations of Lyme disease can be adequately treated with oral antibiotics, intravenous antibiotics are indicated in some individuals with neurologic involvement or atrioventricular heart block. Typical intravenous therapy consists of a 2- to 4-week course of ceftriaxone or cefotaxime, both third-generation cephalosporins, or penicillin or chloramphenicol.
Over-diagnosis and over-treatment of Lyme disease is common due to its nonspecific symptoms, a lack of standardization of serologic tests, and difficulties in interpreting serologic test results. In particular, individuals with chronic fatigue syndrome or fibromyalgia are commonly misdiagnosed as possibly having Lyme disease and undergo inappropriate IV antibiotic therapy.
The Centers for Disease Control and Prevention (CDC) recommends a two-step process when testing blood for evidence of antibodies against the Lyme disease bacteria. Both steps can be done using the same blood sample:
Enzyme-Linked Immunosorbent Assay (ELISA) for Borrelia burgdorferi Antibodies
This is the first step in a two-step process. If this first step is negative, no further testing of the specimen is recommended. If the first step is positive or indeterminate, the second step should be performed. The second step uses a test called an immunoblot test, commonly, a “Western blot” test. Results are considered positive only if the ELISA and the immunoblot are both positive. A positive or indeterminate ELISA test result alone is inadequate serologic evidence of Lyme disease. In addition, results must be correlated with the clinical picture.
Immunoblot (Western blot)
This test is used to confirm the serologic diagnosis of Lyme disease in individuals with positive or indeterminate ELISA tests. In contrast to the standard ELISA test, the immunoblot investigates the specific antibody response to the different antigens of B. burgdorferi. Criteria for interpreting immunoblot results are different in Europe than in the United States due to differences in prevalent Borrelia species.
Other tests include:
Polymerase Chain Reaction (PCR): In contrast to the above 2 serologic tests, which only indirectly assess prior or present exposure to B. burgdorferi, PCR directly tests for the presence of the spirochete. The test cannot distinguish between live spirochetes or fragments of dead ones. The PCR technique has been studied using a variety of specimens. CSF may be positive by PCR during the first two weeks of infection, but thereafter the detection rate is low. PCR is not recommended for urine or blood specimens.
The CDC further recommends not using the following tests:
Capture assays for antigens in urine
Culture, immunofluorescence staining, or cell sorting of cell wall-deficient or cystic forms of B.
Lymphocyte transformation tests
Quantitative CD57 lymphocyte assays
“Reverse Western blots”
Measurements of antibodies in joint fluid (synovial fluid)
IgM or IgG tests without a previous ELISA/EIA/IFA
The terms post-Lyme disease, late Lyme disease, post-treatment chronic Lyme disease, and chronic Lyme disease are intended to describe individuals who have had well-documented Lyme disease, have been treated with antibiotic therapy, and who have continued to be symptomatic. Following antibiotic treatment, some symptoms may persist, such as in Lyme arthritis. These symptoms may be related to various self-sustaining inflammatory mechanisms rather than persistent infection. Based on the available literature, the preferred terminology is late Lyme disease. However, there is no credible evidence to support the existence of continued or chronic infection of the spirochete B. burgdorferi organism itself.
This medical policy does not apply to BlueCare. Please refer to the BlueCare policy.
Testing by the following methods to determine lyme infection is considered medically necessary:
Serologic findings by Enzyme-Linked Immunosorbent Assay (ELISA) for B. burgdorferi antibodies and immunoblot (i.e., Western blot)
Polymerase Chain Reaction (PCR) based direct detection in cerebral spinal fluid (CSF), synovial tissue, or synovial fluid
Treatment for the following conditions is considered medically necessary:
Repeat or prolonged courses of antibiotic therapy greater than 4 weeks are considered not medically necessary.
Other testing, including, but not limited to the following is considered investigational:
Repeat PCR-based direct detection of B. burgdorferi
As a justification for continuation of intravenous antibiotics beyond 1 month in individuals with persistent symptoms
As a technique to follow therapeutic response
PCR-based direct detection of B. burgdorferi in urine samples
Genotyping or phenotyping of B. burgdorferi
Determination of levels of the B lymphocyte chemoattractant CXCL13 for diagnosis or monitoring treatment
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Does not apply to BlueCare, please refer to the BlueCare policy.
No evidence was found to support the safety or efficacy of repeated or prolonged antibiotic treatment (greater than 4 weeks). Fibromyalgia and chronic fatigue syndrome are the diseases most commonly confused with Lyme disease and neither has been shown to be responsive to antibiotic therapy.
No data were found in the published literature to show that repetition of PCR-based direct detection of B. burgdorferi in urine samples, evaluation of the genotype or phenotype of B. burgdorferi, or the B lymphocyte chemoattractant CXCL13 are effective in improving diagnosis, individual management, or outcomes.
BlueCross BlueShield Association. Evidence Positioning System. (10:2017). Intravenous antibiotic therapy and associated diagnostic testing for lyme disease (5.01.08). Retrieved October 1, 2018 from http://www.evidencepositioningsystem.com . (29 articles and/or guidelines reviewed)
Centers for Disease Control and Prevention. (2015, March). Two-step laboratory testing process. Retrieved November 9, 2016 from http://www.cdc.gov.
Centers for Disease Control and Prevention. (2015, November). Laboratory tests that are not recommended. Retrieved December 31, 2015 from http://www.cdc.gov.
Centers for Disease Control and Prevention. (2017, December). Post-treatment lyme disease syndrome. Retrieved October 1, 2018 from http://www.cdc.gov.
Centers for Disease Control and Prevention. (2017, December). Treatment lyme disease. Retrieved October 1, 2018 from http://www.cdc.gov.
Eriksson, P., Schroder, M., Nevanlinna, A., Panelius, J., & Ranke, A. (2013). The many faces of solitary and multiple erythema migrans. Acta Dermato-Venerelogica, 2013 (93), 1-8. (Level 4 evidence)
Infectious Diseases Society of America (IDSA) (2006, reaffirmed in 2010) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Retrieved November 9, 2016 from: http://cid.oxfordjournal.org.
Infectious Diseases Society of America (IDSA) (2018) A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Retrieved October 1, 2018 from http://cid.oxfordjournal.org.
National Institute of Health. National Institute of Allergy and Infectious Diseases. (2015, September) Chronic lyme disease. Retrieved November 9, 2016 from: www.niaid.nih.gov.
National Institute of Health. National Institute of Allergy and Infectious Diseases. (2016, September) Lyme disease diagnostics research. Retrieved November 9, 2016 from: www.niaid.nih.gov.
National Institute of Health. National Institute of Allergy and Infectious Diseases. (2014, December) Lyme disease antibiotic treatment research. Retrieved November 9, 2016 from: www.niaid.nih.gov.
Waddell, L., Greig, J., Mascarenhas, M., harding, S., Lindsay, R., & Ogden, N. (2016). The accuracy of diagnostic tests for lyme disease in humans, a systematic review and meta-analysis of North American research. PLos ONE, 11 (12), doi:10.1371/journal.pone.0168613 (Level 1 evidence)
Wormser, G., Shapiro, E., & Strle, F. (2017). Studies that report unexpected positive blood cultures for lyme Borrelia – are they valid? Diagnostic Microbiology and Infectious Disease, 2017 Jun 29 doi:10.1016/j.diagmicrobio.2017.07.009 [Epub ahead of print]. Abstract retrieved October 16, 2017 from PubMed database.
Yang, J., Han, X., Liu, A., Bao, F., Peng, Y., Tao, L., et al. (2017). Chemokine CXC ligand 13 in cerebrospinal fluid can be used as an early diagnostic biomarker for lyme neuroborreliosis: a meta-analysis. Journal of Interferon & Cytokine Research, 37 (10), 433-439. Abstract retrieved October 16, 2017 from PubMed database.
ORIGINAL EFFECTIVE DATE: 5/9/2009
MOST RECENT REVIEW DATE: 12/13/2018
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.